FerroSens
FerroSens is a Munich-based medical device company (1–10 employees, founded 2017) that sells FIDscreen, a non-invasive point-of-care fluorescence spectroscopy device that measures zinc protoporphyrin on the lower lip to screen for iron deficiency in about one minute, targeting hospitals, pediatricians, and blood donation centers.
- Company typePrivate
- Founded2017
- HeadquartersMunich, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What FerroSens does
FerroSens GmbH is a Munich-based medical device company founded in July 2017 as a spin-off of the Laser Research Laboratory at the University Hospital Munich. The company develops and commercializes FIDscreen, a non-invasive point-of-care medical device that measures zinc protoporphyrin (ZnPP) — an established biomarker for iron deficiency — using optical fluorescence spectroscopy applied to the mucosa of the lower lip, delivering quantitative results in approximately one minute without blood draw. Clinical validation has been conducted on close to 1,000 participants across multi-center studies at University Hospitals in Munich, Frankfurt, and Zürich, demonstrating 97% sensitivity and 90% specificity versus HPLC reference and equivalent diagnostic performance to the full clinical picture in 77% of surgical cases.
The business sells the FIDscreen hardware device and, per the revenue model, generates usage-based revenue from per-test screenings. The primary commercial target is healthcare providers — hospitals, pediatricians, and blood donation centers — with planned expansion into pharmacies (for consumer-direct testing) and sports clubs (for athlete screening), plus a potential adjacent use case in lead poisoning detection. Pricing is not publicly disclosed and the company currently operates with 1–10 employees.
In April 2021, photonamic GmbH & Co. KG, a German medical technology company, acquired a majority stake in FerroSens, providing strategic and financial backing. The underlying measurement site guidance technology is protected by a European patent granted in February 2020, with equivalent filings pending in the US and Asia. The company remains early-stage commercially, with clinical validation activities continuing through at least 2023 and limited disclosed paying-customer base beyond academic study sites.
FerroSens firmographics
Firmographics- Name
- FerroSens
- Legal name
- FerroSens GmbH
- Website
- https://ferrosens.de
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- FerroSens is a Munich-based medical device company (1–10 employees, founded 2017) that sells FIDscreen, a non-invasive point-of-care fluorescence spectroscopy device that measures zinc protoporphyrin on the lower lip to screen for iron deficiency in about one minute, targeting hospitals, pediatricians, and blood donation centers.
- Ownership category
- akta.pro rank
FerroSens industry classification
Industry- Product category
- Non-invasive point-of-care diagnostic medical devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)
Keywords
Where FerroSens is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
FerroSens business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- FIDscreen medical device sales: Sales of FIDscreen point-of-care medical devices for iron deficiency screening to healthcare providers, hospitals, blood donation centers, and future pharmacy/sports club channels.
- Point-of-care testing services: Revenue generated from per-test or per-use basis when healthcare providers perform iron deficiency screenings using the FIDscreen device.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
FerroSens product offering
Product offeringCore offering
FerroSens manufactures and sells FIDscreen, a non-invasive point-of-care medical device that uses optical fluorescence spectroscopy to detect zinc protoporphyrin (ZnPP) on the lower lip as a marker for iron deficiency. The device delivers quantitative results in approximately one minute without requiring blood withdrawal, targeting healthcare providers such as hospitals, pediatric practices, and blood donation centers. The company is positioned as the first non-invasive point-of-care testing device fulfilling the WHO's requirements for iron deficiency screening.
Product overview
FerroSens offers a single core product: FIDscreen, a non-invasive point-of-care medical device for iron deficiency screening. FIDscreen uses optical fluorescence spectroscopy to measure zinc protoporphyrin (ZnPP) levels from the lower lip, providing quantitative results in approximately one minute without blood withdrawal. The company is a spin-off from the Laser Research Laboratory at the University Hospital Munich.
Differentiator
Problem solved
Functional benefit
Brands
- FIDscreen: Medical device for non-invasive detection of zinc protoporphyrin (ZnPP), an established marker for iron deficiency. Uses optical fluorescence spectroscopy method for point-of-care testing on the lower lip.
Products and services
- FIDscreen Non-invasive point-of-care medical device that uses optical fluorescence spectroscopy on the lower lip to quantify zinc protoporphyrin (ZnPP), an established marker for iron deficiency, delivering results in approximately one minute without blood withdrawal. Sold to hospitals, pediatricians, and blood donation centers.
Quantifiable outcome
- 97% sensitivity and 90% specificity in detecting iron deficiency (vs. HPLC reference)
- +3 more outcomes
Companies that use FerroSens
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
FerroSens technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
FerroSens partnerships and signals
Strategic signalScale indicators3 records
Recent moves7 records
Expansion highlights6 records
FerroSens competitors and assessment
Company assessmentDirect peers
- EKF Diagnostics: EKF Diagnostics manufactures point-of-care analyzers for hemoglobin, HbA1c, and related hematology/iron markers used in clinics, blood banks, and sports medicine — directly comparable to FIDscreen's POC screening use cases.
- HemoCue: HemoCue (owned by Radiometer/Danaher) is a direct competitor in point-of-care hemoglobin and anemia screening, including blood donation settings. Both companies target non-invasive or minimally invasive screening for iron-related conditions at the point of care.
Broad incumbents
- Radiometer: Radiometer (part of Danaher) provides acute care diagnostics including blood gas and POC hemoglobin testing, and now owns HemoCue. Comparable as a large POC diagnostics player in hospital and blood-bank settings.
- Masimo: Masimo is a broad-incumbent patient monitoring and non-invasive measurement company (SpHb total hemoglobin, rainbow Pulse CO-Oximetry). Comparable to FerroSens in pioneering non-invasive optical measurement for clinical decision-making, though at much larger scale.
- DiaSys Diagnostic Systems: DiaSys is a clinical chemistry and diagnostic reagents manufacturer with POC and lab-based solutions, including anemia/iron panels. Comparable as a diagnostics provider serving similar clinical laboratory customers in Europe.
- Nova Biomedical: Nova Biomedical manufactures point-of-care blood analysis systems (glucose, lactate, chemistries, hemoglobin) used in hospitals and critical care. Comparable as a POC diagnostics device maker addressing similar customer workflows.
- Siemens Healthineers: Siemens Healthineers offers the epoc and Atellica POC systems alongside broad lab diagnostics including ferritin and iron studies. Comparable as a broad incumbent whose installed analyzers compete with FIDscreen in clinical workflows.
- Abbott Point of Care: Abbott's i-STAT platform is a widely deployed point-of-care diagnostic system in hospitals worldwide. Comparable as a broad incumbent in connected POC clinical testing serving hospitals and emergency settings.
Emerging players
- Eurolyser: Eurolyser manufactures compact point-of-care analyzers (CRP, HbA1c, hemoglobin) for physician offices and pharmacies. Comparable as a smaller, focused POC diagnostics company exploring pharmacy and direct-pay channels similar to FerroSens's planned expansion.
- 77 Elektronika: 77 Elektronika is a European POC diagnostics manufacturer focused on urinalysis, hemoglobin, and HbA1c testing. Comparable as an emerging player in compact POC devices for clinical and consumer channels.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
FerroSens social profiles
Digital presenceFerroSens financial estimates
Financial estimateRevenue estimate
Valuation estimate
FerroSens leadership team
Management profileNumber of profiles
Profiles4 records
FerroSens funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FerroSens M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FerroSens
What does FerroSens do?
FerroSens manufactures and sells FIDscreen, a non-invasive point-of-care medical device that uses optical fluorescence spectroscopy to detect zinc protoporphyrin (ZnPP) on the lower lip as a marker for iron deficiency. The device delivers quantitative results in approximately one minute without requiring blood withdrawal, targeting healthcare providers such as hospitals, pediatric practices, and blood donation centers. The company is positioned as the first non-invasive point-of-care testing device fulfilling the WHO's requirements for iron deficiency screening.
Is FerroSens a public or private company?
FerroSens is a private company. It is classified as corporate owned and is currently operating.
When was FerroSens founded?
FerroSens was founded in 2017. It employs 1 to 10 people.
Where is FerroSens based?
FerroSens is headquartered in Munich, Germany, in the Europe region.
How does FerroSens make money?
Two revenue lines are on record. FIDscreen medical device sales are the primary driver. The others are point-of-care testing services.
Who are FerroSens's main competitors?
Direct peers on record are EKF Diagnostics and HemoCue. Broad incumbents are Radiometer, Masimo, DiaSys Diagnostic Systems, Nova Biomedical, Siemens Healthineers and Abbott Point of Care. Emerging players are Eurolyser and 77 Elektronika.
Does FerroSens have an API?
No public API is recorded for FerroSens.
What industry is FerroSens in?
FerroSens's product category is Non-invasive point-of-care diagnostic medical devices. Its primary akta.pro industry code is HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 334510 and its SIC code is 3845.